Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Satisfaction with Periorbital Aesthetics using JUVÉDERM and BOTOX
NCT05647551Phase 4Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2023
- Primary completion
- Oct 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 4, open-label, single-arm trial of botulinum toxin in rhytides, sponsored by AbbVie Inc. Primary endpoint: Change from baseline in the overall score of the participant's FACE-Q Satisfaction with Eyes at 90 days. Started Jan 2023; status: completed.
02
Drugs
botulinum toxin
03
Conditions
rhytides
Beyond the preview
Go deeper on NCT05647551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05647551.